专题：Melanoma and MAPK Pathways

This cluster of papers focuses on the mammalian MAP kinase signaling pathways, particularly their role in cancer, with a specific emphasis on melanoma. It covers the genetic mutations, targeted therapies, resistance mechanisms, and the impact of MAP kinase pathways on cell proliferation and immune response.
最新文献
The MEK–RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers

article Full Text OpenAlex

Acute Cerebellitis Due to Administration of Durvalumab for Recurrent Endometrial Cancer: A Case Report

article Full Text OpenAlex

The road to therapy for myeloid sarcoma: navigating the complexities of subclonal MAPK / ERK mutations and clonal evolution

article Full Text OpenAlex

A Simplified Classification System for In-Transit Melanoma Metastases

article Full Text OpenAlex

Initial Experience with Transarterial Chemoembolization in Metastatic Cutaneous Melanoma Patients with Hepatic Progression on Immune Checkpoint Inhibitors

article Full Text OpenAlex

STK38 Kinase Promotes Cell Migration Induced by Oncogenic Ras via MerTK Activation

article Full Text OpenAlex

Pharmacophore-based high-throughput virtual screening (HTVS) to identify new c-Src kinase inhibitors with anticancer potential

article Full Text OpenAlex

Therapy-Induced Metastatic Melanoma During Treatment With Encorafenib and Cetuximab for BRAF-Mutated Colorectal Cancer: A Case Report and Short Literature Review

article Full Text OpenAlex

MA02.05 Liquid Biopsy in BRAF V600E NSCLC Treated With Dabrafenib Plus Trametinib: Final Analysis of LiBRA Study (GOIRC-03-2020)

article Full Text OpenAlex

Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status

article Full Text OpenAlex

近5年高被引文献
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

article Full Text OpenAlex 597 FWCI110.47389254

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

article Full Text OpenAlex 557 FWCI82.22851172

Cutaneous melanoma

review Full Text OpenAlex 544 FWCI129.25278244

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

article Full Text OpenAlex 436 FWCI52.67359962

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

article Full Text OpenAlex 420 FWCI78.35291202

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

article Full Text OpenAlex 383 FWCI48.98152488

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

article Full Text OpenAlex 310 FWCI166.70148935

Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update

review Full Text OpenAlex 300 FWCI281.71207085

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

article Full Text OpenAlex 299 FWCI36.42847076

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022

review Full Text OpenAlex 294 FWCI42.75286751